Showing 41-60 of 640 for: Cochrane Systematic Reviews > Cardiovascular 
- Anticoagulation for people with cancer and central venous catheters
Cochrane Systematic Reviews, 1-Jun-2018
Central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis-related morbidity and mortality. This is an update of the Co
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
Cochrane Systematic Reviews, 8-Dec-2021
Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
Cochrane Systematic Reviews, 19-Jun-2018
Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments.
- Anticoagulation versus placebo for heart failure in sinus rhythm
Cochrane Systematic Reviews, 18-May-2021
People with chronic heart failure (HF) are at risk of thromboembolic events, including stroke, pulmonary embolism, and peripheral arterial embolism; coronary ischaemic events also contribute to the progression of HF. The use of long-term oral anticoagulat
- Anticonvulsants for preventing seizures in patients with chronic subdural haematoma
Cochrane Systematic Reviews, 6-Jun-2013
Anticonvulsant therapy is sometimes used prophylactically in patients with chronic subdural haematoma, although the benefit is unclear.
- Antidotes for acute cardenolide (cardiac glycoside) poisoning
Cochrane Systematic Reviews, 12-Oct-2008
Cardenolides are naturally occurring plant toxins which act primarily on the heart. While poisoning with the digitalis cardenolides (digoxin and digitoxin) are reported worldwide, cardiotoxicity from other cardenolides such as the yellow oleander are also
- Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis
Cochrane Systematic Reviews, 21-Apr-2016
Intracranial venous thrombosis (ICVT) commonly presents with seizures in the acute period, and some people may develop recurrent seizures in the long term. The prophylactic use of antiepileptic drugs (AEDs) for the management of post-ICVT seizures is cont
- Antiepileptic drugs for the primary and secondary prevention of seizures after stroke
Cochrane Systematic Reviews, 21-Jan-2014
This is an updated version of the original Cochrane review published in 2010, Issue 1. Seizures after stroke are an important clinical problem, and they may be associated with poor outcome. The effects of antiepileptic drugs for the primary and secondary
- Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
Cochrane Systematic Reviews, 30-Aug-2013
Rebleeding is an important cause of death and disability in people with aneurysmal subarachnoid haemorrhage. Rebleeding is probably related to dissolution of the blood clot at the site of aneurysm rupture by natural fibrinolytic activity. This review is a
- Antifibrinolytic therapy to reduce haemoptysis from any cause
Cochrane Systematic Reviews, 2-Nov-2016
Haemoptysis is a common pathology around the world, occurring with more frequency in low-income countries. It has different etiologies, many of which have infectious characteristics. Antifibrinolytic agents are commonly used to manage bleeding from differ
- Antihypertensive agents for preventing diabetic kidney disease
Cochrane Systematic Reviews, 20-Aug-2013
Various blood pressure-lowering agents, and particularly inhibitors of the renin-angiotensin system (RAS), are widely used for people with diabetes to prevent the onset of diabetic kidney disease (DKD) and adverse cardiovascular outcomes. This is an updat
- Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus
Cochrane Systematic Reviews, 9-Nov-2008
Hypertension and diabetes mellitus are closely associated diseases which are both strongly related to the risk of cardiovascular disease.
- Anti‐inflammatory treatment for carditis in acute rheumatic fever
Cochrane Systematic Reviews, 28-May-2015
Rheumatic heart disease remains an important cause of acquired heart disease in developing countries. Although prevention of rheumatic fever and management of recurrences have been well established, optimal management of active rheumatic carditis remains
- Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases
Cochrane Systematic Reviews, 14-Mar-2012
Our systematic review has demonstrated that antioxidant supplements may increase mortality. We have now updated this review.
- Antiplatelet agents and anticoagulants for hypertension
Cochrane Systematic Reviews, 7-Dec-2011
Elevated systemic blood pressure results in high intravascular pressure but the main complications, coronary heart disease (CHD), ischaemic strokes and peripheral vascular disease (PVD), are related to thrombosis rather than haemorrhage. Some complication
- Antiplatelet agents for intermittent claudication
Cochrane Systematic Reviews, 3-Oct-2011
Peripheral arterial disease (PAD) is common and is a marker of systemic atherosclerosis. Patients with symptoms of intermittent claudication (IC) are at increased risk of cardiovascular events (myocardial infarction (MI) and stroke) and of both cardiovasc
- Antiplatelet agents for preventing pre‐eclampsia and its complications
Cochrane Systematic Reviews, 30-Oct-2019
Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatele
- Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
Cochrane Systematic Reviews, 19-Feb-2015
Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors inf
- Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment
Cochrane Systematic Reviews, 15-Aug-2012
Peripheral arterial disease (PAD) is frequently treated by balloon angioplasty. Restenosis/reocclusion of the dilated segments occurs often, depending on length of occlusion, lower leg outflow, stage of disease and presence of cardiovascular risk factors.
- Antiplatelet and anticoagulation for patients with prosthetic heart valves
Cochrane Systematic Reviews, 9-Jul-2013
Patients with prosthetic heart valves are at increased risk for valve thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet drugs, has been used to minimise this risk. An important issue is the effectiveness
